» Articles » PMID: 7557946

Nodules of Less-differentiated Tumor Within or Adjacent to Hepatocellular Carcinoma: Relative Expression of Transforming Growth Factor-alpha and Its Receptor in the Different Areas of Tumor

Overview
Journal Hum Pathol
Specialty Pathology
Date 1995 Oct 1
PMID 7557946
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Expression of transforming growth factor-alpha (TGF-alpha) and its receptor, the epidermal growth factor receptor (EGFR), in hepatocellular carcinomas (HCCs) and adjacent nontumorous livers from 25 Japanese patients were examined using immunoperoxidase staining of paraffin-embedded sections. TGF-alpha was detected in 24 of 25 (96%) HCCs and 23 of 24 (96%) available adjacent nontumorous livers. EGFR was detected in 16 of 25 (64%) HCCs and 17 of 24 (71%) adjacent nontumorous livers. TGF-alpha and EGFR were not detected by immunohistochemical staining in normal livers. Fifteen of 25 HCCs contained an apparent area of a second tumor (two of the 15 also contained a third tumor) that had a less-differentiated histological grade developing within or adjacent to the first tumor. In those cases, staining in the less-differentiated area of tumor was usually less intense than in the more highly differentiated area (80% of cases for TGF-alpha; 91% for EGFR). These data confirm that increased expression of TGF-alpha and EGFR occur frequently in human HCC. Furthermore, the detection of greater staining in more highly differentiated portions of the tumors suggests that increased expression of TGF-alpha and EGFR may be events of the early stages of human hepatocarcinogenesis.

Citing Articles

Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors.

Akiba J, Ogasawara S, Yano H Cancer Genomics Proteomics. 2024; 21(3):260-271.

PMID: 38670592 PMC: 11059599. DOI: 10.21873/cgp.20445.


Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.

Siddharth S, Kuppusamy P, Wu Q, Nagalingam A, Saxena N, Sharma D Int J Mol Sci. 2022; 23(15).

PMID: 35897659 PMC: 9329836. DOI: 10.3390/ijms23158083.


MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma.

Moon H, Ro S Cancers (Basel). 2021; 13(12).

PMID: 34204242 PMC: 8234271. DOI: 10.3390/cancers13123026.


Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Nguyen K, Jack K, Sun W Diseases. 2017; 4(1).

PMID: 28933381 PMC: 5456309. DOI: 10.3390/diseases4010001.


Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.

Felipe-Silva A, Wakamatsu A, Dos Santos Cirqueira C, Alves V World J Gastroenterol. 2016; 22(27):6246-56.

PMID: 27468214 PMC: 4945983. DOI: 10.3748/wjg.v22.i27.6246.